Meeting
2013 ASCO Annual Meeting
Activity of cetuximab (C) in head and neck squamous cell carcinoma (HNSCC) patients (pts) with PTEN loss or PIK3CA mutation treated on E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C.
Authors
Barbara Burtness
Fox Chase Cancer Center, Philadelphia, PA
Barbara Burtness , Ju-Whei Lee , Donghua Yang , Fang Zhu , Joaquin J. Garcia , Arlene A. Forastiere , Christine H. Chung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6028)
DOI
10.1200/jco.2013.31.15_suppl.6028
Abstract #
6028
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC).
First Author: Samuel J Klempner
Poster
2016 ASCO Annual Meeting
Clinical correlation with codon-specific mutations in metastatic colorectal cancer.
First Author: Sophia C. Kamran
Poster
2015 Breast Cancer Symposium
Association of PIK3CA mutation with response (ExRx) to cetuximab (C) in metastatic (met) triple-negative breast cancer (TNBC).
First Author: Joyce O'Shaughnessy
Poster
2015 ASCO Annual Meeting
Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT.
First Author: Marc Peeters